Rhabdoid Tumor Overview

Save information for later
Sign Up

Learn About Rhabdoid Tumor

What is the definition of Rhabdoid Tumor?
Rhabdoid tumor (RT) is an aggressive pediatric soft tissue sarcoma that arises in the kidney, the liver, the peripheral nerves and all miscellaneous soft-parts throughout the body. RT involving the central nervous system (CNS) is called atypical teratoid Rhabdoid tumor. RT usually occurs in infancy or childhood. In most cases, the first symptoms are linked to the compressive effects of a bulky tumor (such as respiratory distress, abdominal mass, peripheral nerve palsy). In about 90% of cases it is caused by a genetic change in the SMARCB1 gene, which is a tumor suppressor gene. In rare cases, it may be caused by a genetic change in the SMARCA4 gene. No standard care exists for RT, although there are many ongoing studies.
What are the alternative names for Rhabdoid Tumor?
  • Rhabdoid tumor
  • Atypical teratoid rhabdoid tumor
  • BRAIN TUMOR, POSTERIOR FOSSA, OF INFANCY, FAMILIAL
  • Malignant rhabdoid tumor
  • RHABDOID TUMOR PREDISPOSITION SYNDROME 1
  • Rhabdoid sarcoma
  • Rhabdoid tumor predisposition syndrome 2
Who are the top Rhabdoid Tumor Local Doctors?
Mark A. Dickson
Distinguished in Rhabdoid Tumor
Dr. Mark A. Dickson
Hematology Oncology | Hematology | Oncology
Distinguished in Rhabdoid Tumor
Dr. Mark A. Dickson
Hematology Oncology | Hematology | Oncology

Memorial Solid Tumor Group

160 E 53rd St, 
New York, NY 
212-639-2000
Languages Spoken:
English
Offers Telehealth

Mark Dickson is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Dickson and is rated as a Distinguished provider by MediFind in the treatment of Rhabdoid Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Liposarcoma, Undifferentiated Pleomorphic Sarcoma, Fibrosarcoma, and Endoscopy.

Todd W. Bauer
Distinguished in Rhabdoid Tumor
Dr. Todd W. Bauer
Surgical Oncology | General Surgery
Distinguished in Rhabdoid Tumor
Dr. Todd W. Bauer
Surgical Oncology | General Surgery

University Of Virginia Physicians Group

1215 Lee St, 
Charlottesville, VA 
434-243-6868
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Todd Bauer is a Surgical Oncologist and a General Surgeon in Charlottesville, Virginia. Dr. Bauer and is rated as a Distinguished provider by MediFind in the treatment of Rhabdoid Tumor. His top areas of expertise are Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Neuroendocrine Tumor, Hepatectomy, and Pancreaticoduodenectomy. Dr. Bauer is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Rhabdoid Tumor
Yasumichi Kuwahara
Elite in Rhabdoid Tumor
Yasumichi Kuwahara
Kyoto, JP 

Yasumichi Kuwahara practices in Kyoto, Japan. Kuwahara and is rated as an Elite expert by MediFind in the treatment of Rhabdoid Tumor. Their top areas of expertise are Rhabdoid Tumor, RUNX1 Familial Platelet Disorder, Rhabdomyosarcoma, and Ganglioneuroma.

View All Doctors
What are the latest Rhabdoid Tumor Clinical Trials?
Interleukin-15 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as Immunotherapy for Children With Solid Tumors
Interleukin-15 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as Immunotherapy for Children With Solid Tumors
Who is this study for: Children with solid tumors
Enrollment Status: Recruiting
Publish Date: April 17, 2025
Intervention Type: Genetic
Study Drugs: Cytoxan, Fludara
Study Phase: Phase 1

Summary: Patients may be considered if the cancer has come back, has not gone away after standard treatment or the patient cannot receive standard treatment. This research study uses special immune system cells called AGAR T cells, a new experimental treatment. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two d...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
Enrollment Status: Recruiting
Publish Date: April 16, 2025
Intervention Type: Procedure, Other, Biological
Study Phase: Phase 1/Phase 2

Summary: This phase I/II trial studies how well tiragolumab and atezolizumab works when given to children and adults with SMARCB1 or SMARCA4 deficient tumors that have either come back (relapsed) or do not respond to therapy (refractory). SMARCB1 or SMARCA4 deficiency means that tumor cells are missing the SMARCB1 and SMARCA4 genes, seen with some aggressive cancers that are typically hard to treat. Immuno...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center